New Patents Strengthen Privo's Oncology Platform
Recent patent issuances and international allowances strengthen Privo's intellectual property position across topical, intraoperative, and intratumoral delivery technologies BOSTON, Nov. 2, 2026 /PRNewswire/ -- Privo Technologies, Inc., a clinical-stage biopharmaceutical company...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 117 stories mentioning NOV, the earliest published 8 Oct 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.